BioSpace News Archive

Today, the U.S. Food and Drug Administration issued a draft guidance, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” to assist medical product sponsors in submitting Diversity Action Plans to support certain clinical studies.

Nearly one out of four Americans (23.3%) suffer from chronic low back pain. A new study finds that low-intensity continuous ultrasound, such as ZetrOZ Systems’ sustained acoustic medicine (sam®) technology, alleviates the symptoms of chronic lower back pain and reduces the need for pain medication.

Valneva SE announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting held in Lyon, France.

According to latest report, the U.S. Single-use Bioprocessing market size was USD 8.15 billion in 2023, calculated at USD 9.43 billion in 2024, and is expected to reach around USD 35.13 billion by 2033, expanding at a CAGR of 15.73% from 2024 to 2033.

SNP Therapeutics Inc announced today that its Genate Prenatal Nutrition Test can now support healthcare professionals utilizing the Fullscript platform.

Tonix Pharmaceuticals Holding Corp. today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC) today announced that it will host a conference call on Thursday, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT to discuss topline data from the Company’s Phase 2b CARPO trial of Auxora™ in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Nadia Agopyan, Ph.D., RAC, as Senior Vice President of Regulatory Affairs.

CASI Pharmaceuticals, Inc. announced that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other private placement expenses.